These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 9777699)

  • 21. Cell surface expression of the C3b/C4b receptor (CR1) protects Chinese hamster ovary cells from lysis by human complement.
    Makrides SC; Scesney SM; Ford PJ; Evans KS; Carson GR; Marsh HC
    J Biol Chem; 1992 Dec; 267(34):24754-61. PubMed ID: 1447213
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adenovirus-mediated gene transfer to the xenogeneic liver in liver xenotransplantation: the transduction of complement regulatory factor genes (DAF and HRF20).
    Hayashi S; Koike C; Namii Y; Nagasaka T; Katayama A; Saito I; Okada H; Yokoyama I; Ohtsuka S; Uchida K; Takagi H
    Transplant Proc; 1997 Jun; 29(4):2211. PubMed ID: 9193595
    [No Abstract]   [Full Text] [Related]  

  • 23. Prevention of hyperacute rejection by human decay accelerating factor in xenogeneic perfused working hearts.
    Schmoeckel M; Nollert G; Shahmohammadi M; Young VK; Chavez G; Kasper-König W; White DJ; Müller-Höcker J; Arendt RM; Wilbert-Lampen U; Hammer C; Reichart B
    Transplantation; 1996 Sep; 62(6):729-34. PubMed ID: 8824468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury.
    McCurry KR; Kooyman DL; Alvarado CG; Cotterell AH; Martin MJ; Logan JS; Platt JL
    Nat Med; 1995 May; 1(5):423-7. PubMed ID: 7585088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection.
    Dalmasso AP; Vercellotti GM; Platt JL; Bach FH
    Transplantation; 1991 Sep; 52(3):530-3. PubMed ID: 1716798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of various forms of the C1 esterase inhibitor (C1-INH) and DAF on complement mediated xenogeneic cell lysis.
    Fukuta D; Miyagawa S; Yamada M; Matsunami K; Kurihara T; Shirasu A; Hattori H; Shirakura R
    Xenotransplantation; 2003 Mar; 10(2):132-41. PubMed ID: 12588646
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Life-supporting human complement regulator decay accelerating factor transgenic pig liver xenograft maintains the metabolic function and coagulation in the nonhuman primate for up to 8 days.
    Ramirez P; Chavez R; Majado M; Munitiz V; Muñoz A; Hernandez Q; Palenciano CG; Pino-Chavez G; Loba M; Minguela A; Yelamos J; Gago MR; Vizcaino AS; Asensi H; Cayuela MG; Segura B; Marin F; Rubio A; Fuente T; Robles R; Bueno FS; Sansano T; Acosta F; Rodriguez JM; Navarro F; Cabezuelo J; Cozzi E; White DJ; Calne RY; Parrilla P
    Transplantation; 2000 Oct; 70(7):989-98. PubMed ID: 11045632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of the 5'HS4 sequence of the chicken beta-globin locus control region with human EF1 alpha gene promoter induces ubiquitous and high expression of human CD55 and CD59 cDNAs in transgenic rabbits.
    Taboit-Dameron F; Malassagne B; Viglietta C; Puissant C; Leroux-Coyau M; Chéreau C; Attal J; Weill B; Houdebine LM
    Transgenic Res; 1999 Jun; 8(3):223-35. PubMed ID: 10478492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines.
    Hatanaka M; Seya T; Matsumoto M; Hara T; Nonaka M; Inoue N; Takeda J; Shimizu A
    Biochem J; 1996 Mar; 314 ( Pt 3)(Pt 3):969-76. PubMed ID: 8615796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of tandem forms of DAF(CD55) on complement-mediated xenogeneic cell lysis.
    Miyagawa S; Fukuta D; Kitano E; Kobayashi C; Fumimoto Y; Shirasu A; Hattori H; Shirakura R; Fukuzawa M
    Xenotransplantation; 2006 Sep; 13(5):433-9. PubMed ID: 16925667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of hybrid complement regulatory proteins on xenogeneic cells.
    Fukuta D; Miyagawa S; Kubo T; Matsunami K; Shirasu A; Hattori H; Shirakura R
    Biochem Biophys Res Commun; 2003 Jun; 306(2):476-82. PubMed ID: 12804588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of complement regulatory proteins on human eggs and preimplantation embryos.
    Fenichel P; Donzeau M; Cervoni F; Menezo Y; Hsi BL
    Am J Reprod Immunol; 1995 Feb; 33(2):155-64. PubMed ID: 7544131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of a CD46 transgenic pig and protection of transgenic kidneys against hyperacute rejection in non-immunosuppressed baboons.
    Loveland BE; Milland J; Kyriakou P; Thorley BR; Christiansen D; Lanteri MB; Regensburg M; Duffield M; French AJ; Williams L; Baker L; Brandon MR; Xing PX; Kahn D; McKenzie IF
    Xenotransplantation; 2004 Mar; 11(2):171-83. PubMed ID: 14962279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation.
    Kroshus TJ; Salerno CT; Yeh CG; Higgins PJ; Bolman RM; Dalmasso AP
    Transplantation; 2000 Jun; 69(11):2282-9. PubMed ID: 10868627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Production of pigs transgenic for human DAF to overcome complement-mediated hyperacute xenograft rejection in man.
    White DJ; Yannoutsos N
    Res Immunol; 1996 Feb; 147(2):88-94. PubMed ID: 8792466
    [No Abstract]   [Full Text] [Related]  

  • 36. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity.
    Miwa T; Sun X; Ohta R; Okada N; Harris CL; Morgan BP; Song WC
    Immunology; 2001 Oct; 104(2):207-14. PubMed ID: 11683961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The control of hyperacute rejection by genetic engineering of the donor species.
    White DJ; Cozzi E; Langford G; Oglesby T; Wang MW; Wright L; Wallwork J
    Eye (Lond); 1995; 9 ( Pt 2)():185-9. PubMed ID: 7556715
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Construction, expression and functional analysis of a glycolipid-linked form of CR1.
    Clissold PM; Ebling HJ; Lachmann PJ
    Eur J Immunol; 1993 Sep; 23(9):2346-52. PubMed ID: 8370411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of PI-anchored mini-factor H on porcine endothelial cells: potential use in xenotransplantation.
    Yoshitatsu M; Miyagawa S; Mikata S; Matsunami K; Yamada M; Koresawa Y; Sawa Y; Ohtake S; Matsuda H; Shirakura R
    Transplant Proc; 1999 Nov; 31(7):2812-3. PubMed ID: 10578301
    [No Abstract]   [Full Text] [Related]  

  • 40. Different membrane cofactor protein (CD46) isoforms protect transfected cells against antibody and complement mediated lysis.
    Loveland BE; Johnstone RW; Russell SM; Thorley BR; McKenzie IF
    Transpl Immunol; 1993; 1(2):101-8. PubMed ID: 8081768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.